VANCOUVER, April 29, 2013 /CNW/ - Neovasc Inc. ("Neovasc") (TSXV: NVC), today announced financial results for the year ended December 31, 2012. "In 2012 we made substantial progress in every area of our business," said Alexei Marko, CEO of Neovasc. "We continued our robust revenue growth, achieving good sales gains in all three of our businesses. This is the fourth consecutive year that we have achieved an average revenue growth of over 50% in our biological tissue and contract heart valve manufacturing division, as our marketing partner LeMaitre Vascular increased its sales and the cardiac device programs of our industry customers continued to advance towards commercialization.